13601 BMS-986165, an oral selective TYK2 inhibitor, in the treatment of moderate to severe psoriasis as assessed by the static Physicians Global Assessment/body surface area composite tool, a clinically useful alternative to the Psoriasis Area and Severity Index score
Gottlieb A, Strober B, Thaci D, Gordon K, Ren H, Kisa R, Wei L, Banerjee S, Merola J. 13601 BMS-986165, an oral selective TYK2 inhibitor, in the treatment of moderate to severe psoriasis as assessed by the static Physicians Global Assessment/body surface area composite tool, a clinically useful alternative to the Psoriasis Area and Severity Index score. Journal Of The American Academy Of Dermatology 2020, 83: ab120. DOI: 10.1016/j.jaad.2020.06.569.Peer-Reviewed Original ResearchBMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis as Assessed by the Static Physician's Global Assessment (sPGA)/Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI
Gottlieb A, Strober B, Thaçi D, Gordon K, Kundu S, Kisa R, Wei L, Banerjee S, Merola J. BMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis as Assessed by the Static Physician's Global Assessment (sPGA)/Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI. SKIN The Journal Of Cutaneous Medicine 2020, 4: s29. DOI: 10.25251/skin.4.supp.29.Peer-Reviewed Original Research